GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Artemis Medicare Services Ltd

Artemis Medicare Services: Audited Financial Results, Re. 0.45 Dividend Recommended

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 08 May 2026, 06:58 PM IST  ·  BSE ID: 8e6de711-780d-4d68-889b-7a48e9bbca0b
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its latest financial results, recommended a dividend of Re. 0.45, and appointed new independent directors.
🤖 AI Summary
  • Board approved Audited Standalone and Consolidated Financial Results for quarter and year ended March 31, 2026.
  • Recommended Final Dividend of Re. 0.45 per Equity Share (45%) for FY26, subject to shareholder approval.
  • Appointed Mr. Tapan Mitra as Additional Independent Director for 3 years, effective May 8, 2026.
  • Approved seeking shareholder approval for Dr. Girdhar J. Gyani as Independent Director from August 1, 2026.
  • Approved re-appointment of M/s. T R Chadha & Co LLP as Statutory Auditors for five more years.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Final Dividend per Equity Share
Re. 0.45
Dividend Percentage
45%
Independent Director Appointment Term (Tapan Mitra)
3 years
Statutory Auditors Re-appointment Term
5 consecutive years
Extension Period for Preferential Issue Fund Utilization
18 months
🏢 How This Affects the Company
💰
Financial Impact
The recommendation of a final dividend indicates a distribution of profits to shareholders, impacting retained earnings and cash flow upon payment. The extension of the utilization period for preferential issue funds affects the company's capital deployment timeline.
⚙️
Operational Impact
The appointment and proposed re-appointment of Independent Directors will impact the composition and governance structure of the Board. The re-appointment of statutory auditors ensures continuity in external financial oversight.
⚠️
Risk Impact
Shareholder approval is required for dividend payment, director appointments, and auditor re-appointment, which represents a procedural risk. The extension of fund utilization period introduces timing risk regarding project deployment.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must vote on the final dividend, director appointments, and auditor re-appointment at the upcoming Annual General Meeting.
👤
Who Is Affected
All shareholders are affected by the dividend recommendation of Re. 0.45 per Equity Share. Shareholders will also determine the composition of the Board and the appointment of the statutory auditors.
🔍
Management Signal
The management's decision to recommend a dividend and appoint new independent directors signals a commitment to shareholder returns and strengthened corporate governance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Outcome of the Annual General Meeting for dividend and director approvals.
Details of the full Audited Financial Results (Standalone and Consolidated).
Further updates on the utilization of preferential issue funds after the extended period.
LOW RISK The filing primarily details routine financial disclosures and governance decisions, subject to shareholder approval.
💡 Investor Takeaway
Artemis Medicare Services' Board approved FY26 audited financial results and recommended a final dividend of Re. 0.45 per Equity Share. New independent directors have been appointed and auditor re-appointment is proposed, all subject to shareholder approval.
⚖️ Strengths & Concerns

✅ Positives

  • Recommended a final dividend of Re. 0.45 per Equity Share (45%) for FY26, signaling distribution of profits to shareholders.
  • Appointed new Independent Directors and proposed re-appointment of existing ones, strengthening board governance and oversight.
📅 Company Track Record
No previous filings containing specific historical financial data, order wins, or dividend history for Artemis Medicare Services Ltd were found in the provided context to establish a historical note.

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.